Syndax Pharmaceuticals (SNDX) to Release Quarterly Earnings on Tuesday

Syndax Pharmaceuticals (NASDAQ:SNDX) will post its quarterly earnings results after the market closes on Tuesday, November 5th. Analysts expect Syndax Pharmaceuticals to post earnings of ($1.13) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.11. The firm had revenue of $3.50 million for the quarter. The business’s revenue was up 3499999990.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.64) earnings per share. On average, analysts expect Syndax Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syndax Pharmaceuticals Trading Up 0.6 %

Syndax Pharmaceuticals stock opened at $18.98 on Monday. The stock has a fifty day simple moving average of $19.11 and a two-hundred day simple moving average of $20.33. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -5.62 and a beta of 0.92. Syndax Pharmaceuticals has a 12 month low of $13.14 and a 12 month high of $25.34.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on SNDX shares. Citigroup increased their target price on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 16th. Barclays upped their target price on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a report on Thursday, August 15th. Bank of America boosted their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, August 15th. HC Wainwright increased their target price on Syndax Pharmaceuticals from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Finally, Stifel Nicolaus lifted their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.90.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).